These transdermal patches dont actually have any active GLP-1 medicine in them, says Richele Corrado, DO, MPH, FACP, Internal & Obesity Medicine Physician at Revolution Medicine, Health & Fitness
18 For those patients not achieving desired glycemic control at 1.2 mg, the dose can be increased to 1.8 mg
This is where it helps to slow down and make peace with smaller portions
Despite CJC-1295s believed impact on weight loss and body composition, there remains a lack of data to indicate the specific dose or duration it may be administered to these ends
Survodutides dataset is smaller and still expanding, which means researchers comparing the two are often comparing a well-documented compound against one with a thinner but growing evidence base